The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin

Ruud P M Dings, Yumi Yokoyama, Sundaram Ramakrishnan, Arjan W. Griffioen, Kevin H. Mayo

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Recently, we demonstrated that the designed peptide anginex displays potent antiangiogenic activity. The aim of the present study was to investigate anginex treatment as a single-agent therapy and to test its ability to improve conventional chemotherapy and antiangiogenesis therapy. In a human ovarian carcinoma mouse model, anginex inhibited tumor growth by 70%. When anginex was combined with a suboptimal dose of carboplatin, tumors regressed to an impalpable state. Anginex plus angiostatin worked synergistically to inhibit tumor growth. Assessment of microvessel density suggested that the antitumor activity of anginex is mediated by angiogenesis inhibition. In any of the experiments, no sign of anginexinduced toxicity was observed.

Original languageEnglish (US)
Pages (from-to)382-385
Number of pages4
JournalCancer Research
Volume63
Issue number2
StatePublished - Jan 15 2003
Externally publishedYes

Fingerprint

Angiostatic Proteins
Angiostatins
Drug Therapy
Neoplasms
Carboplatin
Growth
Microvessels
Therapeutics
Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. / Dings, Ruud P M; Yokoyama, Yumi; Ramakrishnan, Sundaram; Griffioen, Arjan W.; Mayo, Kevin H.

In: Cancer Research, Vol. 63, No. 2, 15.01.2003, p. 382-385.

Research output: Contribution to journalArticle

Dings, Ruud P M ; Yokoyama, Yumi ; Ramakrishnan, Sundaram ; Griffioen, Arjan W. ; Mayo, Kevin H. / The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. In: Cancer Research. 2003 ; Vol. 63, No. 2. pp. 382-385.
@article{a9872963684240c39a332a4cdbf97e84,
title = "The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin",
abstract = "Recently, we demonstrated that the designed peptide anginex displays potent antiangiogenic activity. The aim of the present study was to investigate anginex treatment as a single-agent therapy and to test its ability to improve conventional chemotherapy and antiangiogenesis therapy. In a human ovarian carcinoma mouse model, anginex inhibited tumor growth by 70{\%}. When anginex was combined with a suboptimal dose of carboplatin, tumors regressed to an impalpable state. Anginex plus angiostatin worked synergistically to inhibit tumor growth. Assessment of microvessel density suggested that the antitumor activity of anginex is mediated by angiogenesis inhibition. In any of the experiments, no sign of anginexinduced toxicity was observed.",
author = "Dings, {Ruud P M} and Yumi Yokoyama and Sundaram Ramakrishnan and Griffioen, {Arjan W.} and Mayo, {Kevin H.}",
year = "2003",
month = "1",
day = "15",
language = "English (US)",
volume = "63",
pages = "382--385",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin

AU - Dings, Ruud P M

AU - Yokoyama, Yumi

AU - Ramakrishnan, Sundaram

AU - Griffioen, Arjan W.

AU - Mayo, Kevin H.

PY - 2003/1/15

Y1 - 2003/1/15

N2 - Recently, we demonstrated that the designed peptide anginex displays potent antiangiogenic activity. The aim of the present study was to investigate anginex treatment as a single-agent therapy and to test its ability to improve conventional chemotherapy and antiangiogenesis therapy. In a human ovarian carcinoma mouse model, anginex inhibited tumor growth by 70%. When anginex was combined with a suboptimal dose of carboplatin, tumors regressed to an impalpable state. Anginex plus angiostatin worked synergistically to inhibit tumor growth. Assessment of microvessel density suggested that the antitumor activity of anginex is mediated by angiogenesis inhibition. In any of the experiments, no sign of anginexinduced toxicity was observed.

AB - Recently, we demonstrated that the designed peptide anginex displays potent antiangiogenic activity. The aim of the present study was to investigate anginex treatment as a single-agent therapy and to test its ability to improve conventional chemotherapy and antiangiogenesis therapy. In a human ovarian carcinoma mouse model, anginex inhibited tumor growth by 70%. When anginex was combined with a suboptimal dose of carboplatin, tumors regressed to an impalpable state. Anginex plus angiostatin worked synergistically to inhibit tumor growth. Assessment of microvessel density suggested that the antitumor activity of anginex is mediated by angiogenesis inhibition. In any of the experiments, no sign of anginexinduced toxicity was observed.

UR - http://www.scopus.com/inward/record.url?scp=0037439824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037439824&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 382

EP - 385

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 2

ER -